---
title: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence
nct_id: NCT03152903
overall_status: COMPLETED
phase: PHASE2, PHASE3
sponsor: Serum Institute of India Pvt. Ltd.
study_type: INTERVENTIONAL
primary_condition: Prevention of TB Recurrence
countries: Bangladesh, India
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03152903.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03152903"
ct_last_update_post_date: 2025-05-18
last_seen_at: "2026-05-12T07:02:11.614Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence

**Official Title:** A Multicenter Phase II/III Double-Blind, Randomized, Placebo Controlled Study To Evaluate The Efficacy And Safety Of VPM1002 In The Prevention Of Tuberculosis (TB) Recurrence In Pulmonary TB Patients After Successful TB Treatment

**NCT ID:** [NCT03152903](https://clinicaltrials.gov/study/NCT03152903)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2, PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 2000
- **Lead Sponsor:** Serum Institute of India Pvt. Ltd.
- **Conditions:** Prevention of TB Recurrence
- **Start Date:** 2017-12-15
- **Completion Date:** 2023-12-29
- **CT.gov Last Update:** 2025-05-18

## Brief Summary

This is a Phase II/III trial with two groups of adults successfully cured of category 1 pulmonary TB receiving either VPM1002 or placebo. Single dose of VPM1002 / placebo will be administered to calculate efficacy of the vaccine against TB recurrence.

## Detailed Description

The study is designed as a multicenter, double-blinded, randomized, placebo-controlled trial with two groups of category 1 pulmonary TB patients who have successfully completed ATT and declared cured by bacteriological confirmation.

The eligible participants will be randomized in 1:1 ratio to receive single dose of either VPM1002 or placebo. After study vaccination, participants will be followed up for one year. Any suspected TB case during follow up will be further evaluated and bacteriologically confirmed. Study participants will be actively followed up for 2 months post-vaccination for any solicited local and regional reaction. SAEs will be recorded and reported throughout study participation.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Males or females aged ≥18 and ≤65 years.
2. Bacteriologically confirmed Category I pulmonary TB patients (including controlled diabetics with HbA1c level ≤7% and non-diabetics) who successfully completed ATT as per national guidelines.
3. Must have a sputum sample showing bacteriologic confirmation of cure - defined as smear negative.
4. Female participants who are currently using reliable methods of birth control, have a negative pregnancy test during screening and have no intention to become pregnant for at least 3 months post-vaccination.
5. Participant must intend to remain in the area during the study period.

Exclusion Criteria:

1. Reactive serology for HIV
2. History of extrapulmonary TB
3. Known or suspected impairment of immunological function
4. Pregnant and / or lactating female participants
```

## Arms

- **VPM1002 (Recombinant BCG vaccine)** (EXPERIMENTAL)
- **Placebo** (PLACEBO_COMPARATOR)

## Interventions

- **VPM1002 (Recombinant BCG Vaccine)** (BIOLOGICAL) — VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.

VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+. Single dose of VPM1002 is administered intradermally.
- **Placebo** (OTHER) — Single dose of Placebo is administered intradermally.

## Primary Outcomes

- **Percentage of bacteriologically confirmed TB recurrence cases** _(time frame: 2-12 months post-vaccination)_ — Percentage of TB recurrence patients who have previously been successfully treated for TB, were declared cure and are now diagnosed with a new episode of bacteriologically confirmed recurrent TB after at least 2 months from vaccination.

## Secondary Outcomes

- **Percentage of overall TB recurrence (i.e. either bacteriologically confirmed or clinically diagnosed TB recurrence)** _(time frame: 2-12 months post-vaccination)_
- **Safety assessed by Solicited local and regional reactogenicity and Unsolicited adverse events and SAEs** _(time frame: Throughout study participation i.e.12 months post-vaccination)_

## Locations (10)

- International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh
- Mahavir Hospital & Research Centre, Hyderabad, Hyderabad, Andhra Pradesh, India
- Government Medical College, Jammu, Jammu, Jammu and Kashmir, India
- B.J. Govt. Medical College and Sassoon General Hospitals, Pune, Maharashtra, India
- Mahatma Gandhi Institute of Medical Sciences, Sevagram, Sevāgrām, Maharashtra, India
- Christian Medical College and Hospital, Ludhiana, Ludhiana, Punjab, India
- MV Hopsital for Diabetes Pvt Ltd, Chennai, Chennai, Tamil Nadu, India
- Sri Ramachandra Hospital Chennai, Chennai, Tamil Nadu, India
- Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, Tamil Nadu, India
- Christian Medical College and Hospital, Vellore, Vellore, Tamil Nadu, India

## Recent Field Changes (last 30 days)

- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.international centre for diarrhoeal disease research|dhaka||bangladesh` — added _(2026-05-12)_
- `locations.mahavir hospital & research centre, hyderabad|hyderabad|andhra pradesh|india` — added _(2026-05-12)_
- `locations.government medical college, jammu|jammu|jammu and kashmir|india` — added _(2026-05-12)_
- `locations.b.j. govt. medical college and sassoon general hospitals|pune|maharashtra|india` — added _(2026-05-12)_
- `locations.mahatma gandhi institute of medical sciences, sevagram|sevāgrām|maharashtra|india` — added _(2026-05-12)_
- `locations.christian medical college and hospital, ludhiana|ludhiana|punjab|india` — added _(2026-05-12)_
- `locations.mv hopsital for diabetes pvt ltd, chennai|chennai|tamil nadu|india` — added _(2026-05-12)_
- `locations.sri ramachandra hospital chennai|chennai|tamil nadu|india` — added _(2026-05-12)_
- `locations.jawaharlal institute of postgraduate medical education and research, puducherry|puducherry|tamil nadu|india` — added _(2026-05-12)_
- `locations.christian medical college and hospital, vellore|vellore|tamil nadu|india` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03152903.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03152903*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*